. Polycystic Ovary Syndrome and Metabolic Disorders

GISELLE ADRIANA ABRUZZESE; MARIA FLORENCIA HEBER; LEANDRO MARTIN VELEZ; OSCAR LEVALLE; MABEL GRAFFIGNA; SUSANA BELLI; CECILIA GORLA; EDUARDO MORMANDI; PATRICIA OTERO; ALICIA BEATRIZ MOTTA

Chascomus

Congreso; XVI Jornadas Anuales de la SAB; 2014

SAB

PCOS AND METABOLIC DISORDERS Abruzzese GA, Heber MF, Vélez LM, Levalle O, Graffigna M, Belli S, Gorla C, Mormandi E, Otero P, Motta AB. CEFYBO-UBA-CONICET, Hospital Durand Polycystic ovary syndrome (PCOS) is a common disease affecting women in their reproductive age. PCOS is diagnosed by two of these alterations:clinical or biochemical hyperandrogenism, oligo or anovulation and ovarian cysts. PCOS could be classified in two main phenotypes: hyperandrogenic (HA)(clinical and or biochemical hyperandrogenism) and no hyperandrogenic (NHA) phenotype. We divided a group of 30 PCOS patients from Hospital Durand into HA and NHA phenotype and studied the relation between its phenotypes and the presence of Metabolic Syndrome(MetS). The analysis showed that 60% of the patients displayed HA phenotype.The prescence of MetS was independent of the phenotype.The HA showed similar levels of triglyceride, HDL cholesterol, homeostasis index, glycemia, insulin, and 17 beta hidroxy steroid dehydrogenase activity as compared with NHA. HA women showed increased levels of total and LDL cholesterol and activity of P450 c17 lyase. In the HA group, hyperandrogenemia did not reflect clinical hyperandrogenism found in that patients. We conclude that hyperandrogenism may be affected by the increase on androgen production and not by the levels of the circulating androgens. We also found that the prevalence of MetS is independent of the PCOS phenotype.